Breaking
Medicus Pharma Ltd. to Present at Biotech Showcase 2026, Advancing SkinJect ProgramEli Lilly's Legal Victory Over Noom's GLP-1 ClaimsBBSW AI Solution Event: Daily Roundup
🇺🇸 FDA

SKNY-1 News

🇺🇸 Americas ← All news

FDA SKNY-1 coverage for business development, investment, and market access teams

Latest on SKNY-1

MIRA Pharma Consolidates Global Rights to MIRA-55 and SKNY-1
NewsJun 5, 2026

MIRA Pharma Consolidates Global Rights to MIRA-55 and SKNY-1

MIRA Pharmaceuticals amends its MIRALOGX license to secure worldwide exclusive development and commercialization rights for MIRA-55 and SKNY-1, without altering core economics. The move strengthens IP control and follows peer-reviewed data on SKNY-1's obesity and nicotine addiction potential.

Dr. Sarah Mitchell

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.